EEC MARKETING AUTHORIZATION OF MEDICINAL PRODUCTS

被引：0
|
作者：
MIKHAIL, M
机构：
来源：
TIERARZTLICHE UMSCHAU | 1992年 / 47卷 / 05期
关键词：
VETERINARY MEDICINAL PRODUCTS; MARKETING AUTHORIZATION; EEC LEGAL REQUIREMENTS; APPLICATION FOR MARKETING AUTHORIZATION; COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS CVMP; PRESCRIPTION ONLY MEDICINE POM; EUROPEAN AGENCY; PHARMACOVIGILANCE; PREMIXES; HIGHTECH MEDICINAL PRODUCTS; MAXIMAL RESIDUE LIMITS MRL; HARMONIZATION;
D O I：
暂无
中图分类号：
S85 [动物医学（兽医学）];
学科分类号：
0906 ;
摘要：
An overview of the legal requirements imposed by the EEC for the marketing authorization of a medicinal product is given which highlights those for veterinary medicinal products. These include the EC directives 81/851, 81/852 and their amendments for the application for marketing authorization, the Committee for Veterinary Medicinal Products COM 90/C 330 on establishing a European Agency and on pharmaco vigilance, 90/167 on pre-mixes, 90/676 on prescription requirements, 87/22 on medicinal products produced by high technology methods and 2377/90 on Maximum Residue Limits (MRL's). Areas which are of concern include the future registration system and the future distribution channels with respect to a harmonised EEC-wide prescription only medicine (POM) policy.
引用
收藏
页码：387 / &
相关论文
共 50 条
  • [31] Marketing of veterinary medicinal products via the internet - a drug safety problem?
    Wilke, A.
    Ibrahim, C.
    [J]. JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2009, 32 : 117 - 117
  • [32] Presentation and distribution of medicinal products after the new EU marketing procedures
    Montanari, L
    Minghetti, P
    Giudici, EM
    [J]. PHARMACOLOGICAL RESEARCH, 1997, 35 (01) : 37 - 42
  • [33] RESTRICTIONS ON THE REIMBURSEMENT POLICY WITH REGARD TO RETAIL MARKETING OF MEDICINAL PRODUCTS IN POLAND
    Zimmermann, Agnieszka
    [J]. ACTA POLONIAE PHARMACEUTICA, 2013, 70 (02): : 339 - 343
  • [34] EUROPEAN CONDITIONAL MARKETING AUTHORIZATION - DOES EARLY MARKETING AUTHORIZATION TRANSLATE INTO EARLY REIMBURSEMENT AND PATIENT ACCESS?
    Macaulay, R.
    Rothwell, S.
    Sutcliffe, D.
    [J]. VALUE IN HEALTH, 2018, 21 : S160 - S160
  • [35] EEC RESTRICTIONS THREATEN MEAL MARKETING
    不详
    [J]. RICE JOURNAL, 1978, 81 (10): : 8 - 9
  • [36] Procedure for the marketing authorization of an antibacterial agent
    Lopez Navas, Antonio
    Garcia-Escribano Raez, Nuria
    Flores Juberias, Angela
    Suarez Gea, Maria Luisa
    [J]. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2014, 32 (08): : 529 - 532
  • [37] Appropriate evidence for adaptive marketing authorization
    de Jong, Jean Philippe
    Grobbee, Diederick E.
    Flamion, Bruno
    Forda, Susan R.
    Leufkens, Hubert G. M.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2013, 12 (09) : 647 - 648
  • [38] Suspension of marketing authorization for ingenol mebutate
    Mohd Mustapa, M. F.
    de Berker, D.
    McGregor, J. M.
    Exton, L. S.
    Hughes, B. R.
    Levell, N. J.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (04) : 792 - 792
  • [39] Appropriate evidence for adaptive marketing authorization
    Jean Philippe de Jong
    Diederick E. Grobbee
    Bruno Flamion
    Susan R. Forda
    Hubert G. M. Leufkens
    [J]. Nature Reviews Drug Discovery, 2013, 12 : 647 - 648
  • [40] The prescription without marketing authorization in general
    Hurtaud, Aline
    Lebeau, Jean-Pierre
    [J]. EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE, 2012, 23 (100): : 44 - 45
12345